Advertisement

European Radiology

, Volume 27, Issue 7, pp 3088–3096 | Cite as

Disappearing or residual tiny (≤5 mm) colorectal liver metastases after chemotherapy on gadoxetic acid-enhanced liver MRI and diffusion-weighted imaging: Is local treatment required?

  • Seung Soo Kim
  • Kyoung Doo Song
  • Young Kon Kim
  • Hee Cheol Kim
  • Jung Wook Huh
  • Young Suk Park
  • Joon Oh Park
  • Seung Tae Kim
Gastrointestinal

Abstract

Objectives

To evaluate the clinical course of disappearing colorectal liver metastases (DLM) or residual tiny (≤5 mm) colorectal liver metastases (RTCLM) on gadoxetic acid-enhanced magnetic resonance imaging (MRI) and diffusion-weighted imaging (DWI) in patients who had colorectal liver metastases (CLM) and received chemotherapy.

Methods

Among 137 patients who received chemotherapy for CLM and underwent gadoxetic acid-enhanced MRI and DWI between 2010 and 2012, 43 patients with 168 DLMs and 48 RTCLMs were included. The cumulative in situ recurrence rate of DLM and progression rate of RTCLM and their predictive factors were evaluated.

Results

A total of 150 DLMs and 26 RTCLMs were followed up without additional treatment. At 1 and 2 years, respectively, the cumulative in situ recurrence rates for DLM were 10.9 % and 15.7 % and the cumulative progression rates for RTCLM were 27.2 % and 33.2 %. The in situ recurrence rate at 2 years was 4.9 % for the DLM group that did not show reticular hypointensity of liver parenchyma on hepatobiliary phase.

Conclusions

DLM on gadoxetic acid-enhanced liver MRI and DWI indicates a high possibility of clinical complete response, especially in patients without chemotherapy-induced sinusoidal obstruction syndrome. Thirty-three percent of RTCLMs showed progression at 2 years.

Key Points

DLMs on gadoxetic acid-enhanced MRI and DWI showed low recurrence rates.

If there is sinusoidal obstruction syndrome, evaluation of DLM needs special care.

The progression rate for residual tiny CLMs was 33.2 % at 2 years.

Keywords

Colorectal liver metastasis Gadoxetic acid-enhanced MRI Chemotherapy Disappearing metastasis Residual tiny metastasis 

Abbreviations

ADC

Apparent diffusion coefficient

CLM

Colorectal liver metastases

CR

Complete response

CT

Computed tomography

DLM

Disappearing liver metastases

DWI

Diffusion-weighted imaging

MRI

Magnetic resonance imaging

RTCLM

Residual tiny colorectal liver metastases

Notes

Acknowledgements

The scientific guarantor of this publication is Won Jae Lee, the head of radiology department. The authors of this manuscript declare no relationships with any companies whose products or services may be related to the subject matter of the article. The authors state that this work has not received any funding. Kyung A. Kim from the Center for Biostatistics and Clinical Epidemiology (Samsung Medical Center) kindly provided statistical advice for this manuscript. This study was performed on human subjects. Institutional Review Board approval was obtained. Written informed consent was waived by the Institutional Review Board. No study subjects or cohorts have been previously reported. Methodology: retrospective, observational, performed at one institution.

References

  1. 1.
    Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D (2011) Global cancer statistics. CA Cancer J Clin 61:69–90CrossRefPubMedGoogle Scholar
  2. 2.
    Manfredi S, Lepage C, Hatem C, Coatmeur O, Faivre J, Bouvier AM (2006) Epidemiology and management of liver metastases from colorectal cancer. Ann Surg 244:254–259CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Scheele J, Stang R, Altendorf-Hofmann A, Paul M (1995) Resection of colorectal liver metastases. World J Surg 19:59–71CrossRefPubMedGoogle Scholar
  4. 4.
    Zavadsky KE, Lee YT (1994) Liver metastases from colorectal carcinoma: incidence, resectability, and survival results. Am Surg 60:929–933PubMedGoogle Scholar
  5. 5.
    Chua TC, Saxena A, Liauw W, Kokandi A, Morris DL (2010) Systematic review of randomized and nonrandomized trials of the clinical response and outcomes of neoadjuvant systemic chemotherapy for resectable colorectal liver metastases. Ann Surg Oncol 17:492–501CrossRefPubMedGoogle Scholar
  6. 6.
    Benoist S, Brouquet A, Penna C et al (2006) Complete response of colorectal liver metastases after chemotherapy: does it mean cure? J Clin Oncol 24:3939–3945CrossRefPubMedGoogle Scholar
  7. 7.
    Kim HJ, Lee SS, Byun JH et al (2015) Incremental value of liver MR imaging in patients with potentially curable colorectal hepatic metastasis detected at CT: a prospective comparison of diffusion-weighted imaging, gadoxetic acid-enhanced MR imaging, and a combination of both MR techniques. Radiology 274:712–722CrossRefPubMedGoogle Scholar
  8. 8.
    Scharitzer M, Ba-Ssalamah A, Ringl H et al (2013) Preoperative evaluation of colorectal liver metastases: comparison between gadoxetic acid-enhanced 3.0-T MRI and contrast-enhanced MDCT with histopathological correlation. Eur Radiol 23:2187–2196CrossRefPubMedGoogle Scholar
  9. 9.
    Muhi A, Ichikawa T, Motosugi U et al (2011) Diagnosis of colorectal hepatic metastases: comparison of contrast-enhanced CT, contrast-enhanced US, superparamagnetic iron oxide-enhanced MRI, and gadoxetic acid-enhanced MRI. J Magn Reson Imaging 34:326–335CrossRefPubMedGoogle Scholar
  10. 10.
    Owen JW, Fowler KJ, Doyle MB, Saad NE, Linehan DC, Chapman WC (2016) Colorectal liver metastases: disappearing lesions in the era of Eovist hepatobiliary magnetic resonance imaging. HPB (Oxford) 18:296–303CrossRefGoogle Scholar
  11. 11.
    Kim A, Lee CH, Kim BH et al (2012) Gadoxetic acid-enhanced 3.0T MRI for the evaluation of hepatic metastasis from colorectal cancer: metastasis is not always seen as a "defect" on the hepatobiliary phase. Eur J Radiol 81:3998–4004CrossRefPubMedGoogle Scholar
  12. 12.
    Lee EW, Wei LJ, Amato DA (1992) Cox-type regression analysis for large number of small groups of correlated failure time observations. In: Klein JP, Goel PK (eds) Survival analysis, state of the art. Kluwer Academic Publishers, Dordrecht, pp 237–247CrossRefGoogle Scholar
  13. 13.
    Auer RC, White RR, Kemeny NE et al (2010) Predictors of a true complete response among disappearing liver metastases from colorectal cancer after chemotherapy. Cancer 116:1502–1509CrossRefPubMedGoogle Scholar
  14. 14.
    Elias D, Goere D, Boige V et al (2007) Outcome of posthepatectomy-missing colorectal liver metastases after complete response to chemotherapy: impact of adjuvant intra-arterial hepatic oxaliplatin. Ann Surg Oncol 14:3188–3194CrossRefPubMedGoogle Scholar
  15. 15.
    Elias D, Youssef O, Sideris L et al (2004) Evolution of missing colorectal liver metastases following inductive chemotherapy and hepatectomy. J Surg Oncol 86:4–9CrossRefPubMedGoogle Scholar
  16. 16.
    Tanaka K, Takakura H, Takeda K, Matsuo K, Nagano Y, Endo I (2009) Importance of complete pathologic response to prehepatectomy chemotherapy in treating colorectal cancer metastases. Ann Surg 250:935–942CrossRefPubMedGoogle Scholar
  17. 17.
    van Vledder MG, de Jong MC, Pawlik TM, Schulick RD, Diaz LA, Choti MA (2010) Disappearing colorectal liver metastases after chemotherapy: should we be concerned? J Gastrointest Surg 14:1691–1700CrossRefPubMedGoogle Scholar
  18. 18.
    Gaujoux S, Goere D, Dumont F et al (2011) Complete radiological response of colorectal liver metastases after chemotherapy: what can we expect? Dig Surg 28:114–120CrossRefPubMedGoogle Scholar
  19. 19.
    Yu MH, Lee JM, Hur BY et al (2015) Gadoxetic acid-enhanced MRI and diffusion-weighted imaging for the detection of colorectal liver metastases after neoadjuvant chemotherapy. Eur Radiol 25:2428–2436CrossRefPubMedGoogle Scholar
  20. 20.
    Kim YK, Lee MW, Lee WJ et al (2012) Diagnostic accuracy and sensitivity of diffusion-weighted and of gadoxetic acid-enhanced 3-T MR imaging alone or in combination in the detection of small liver metastasis (</= 1.5 cm in diameter). Investig Radiol 47:159–166Google Scholar
  21. 21.
    Koh DM, Collins DJ, Wallace T, Chau I, Riddell AM (2012) Combining diffusion-weighted MRI with Gd-EOB-DTPA-enhanced MRI improves the detection of colorectal liver metastases. Br J Radiol 85:980–989CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Macera A, Lario C, Petracchini M et al (2013) Staging of colorectal liver metastases after preoperative chemotherapy. Diffusion-weighted imaging in combination with Gd-EOB-DTPA MRI sequences increases sensitivity and diagnostic accuracy. Eur Radiol 23:739–747CrossRefPubMedGoogle Scholar
  23. 23.
    Shin NY, Kim MJ, Lim JS et al (2012) Accuracy of gadoxetic acid-enhanced magnetic resonance imaging for the diagnosis of sinusoidal obstruction syndrome in patients with chemotherapy-treated colorectal liver metastases. Eur Radiol 22:864–871CrossRefPubMedGoogle Scholar
  24. 24.
    Tamandl D, Klinger M, Eipeldauer S et al (2011) Sinusoidal obstruction syndrome impairs long-term outcome of colorectal liver metastases treated with resection after neoadjuvant chemotherapy. Ann Surg Oncol 18:421–430CrossRefPubMedGoogle Scholar
  25. 25.
    Angliviel B, Benoist S, Penna C et al (2009) Impact of chemotherapy on the accuracy of computed tomography scan for the evaluation of colorectal liver metastases. Ann Surg Oncol 16:1247–1253CrossRefPubMedGoogle Scholar
  26. 26.
    Aloysius MM, Zaitoun AM, Beckingham IJ et al (2007) The pathological response to neoadjuvant chemotherapy with FOLFOX-4 for colorectal liver metastases: a comparative study. Virchows Arch 451:943–948CrossRefPubMedGoogle Scholar

Copyright information

© European Society of Radiology 2016

Authors and Affiliations

  • Seung Soo Kim
    • 1
    • 2
  • Kyoung Doo Song
    • 1
  • Young Kon Kim
    • 1
  • Hee Cheol Kim
    • 3
  • Jung Wook Huh
    • 3
  • Young Suk Park
    • 4
  • Joon Oh Park
    • 4
  • Seung Tae Kim
    • 4
  1. 1.Department of Radiology and Center for Imaging Science, Samsung Medical CenterSungkyunkwan University School of MedicineSeoulRepublic of Korea
  2. 2.Department of Radiology, Soonchunhyang University College of MedicineCheonan HospitalCheonan-siRepublic of Korea
  3. 3.Department of Surgery, Samsung Medical CenterSungkyunkwan University School of MedicineSeoulRepublic of Korea
  4. 4.Division of Hematology-Oncology, Department of Medicine, Samsung Medical CenterSungkyunkwan University School of MedicineSeoulRepublic of Korea

Personalised recommendations